Why Is Athira Pharma Stock Spiking After Breast Cancer Asset Acquisition?

Athira Pharma Inc. (NASDAQ:ATHA) stock is trading higher on Thursday, with a session volume of 57.29 million compared to the average volume of 30.94 thousand as per data from Benzinga Pro.Athira Pharma on Thursday agreed to acquire the rights for the development and commercialization of lasofoxifene, a clinical asset in a potentially registrational Phase 3 trial.The ongoing Phase 3 ELAINE-3 clinical trial is greater than 50% enrolled, with data expected in mid-2027.Athira has acquired an exclusive global li ...